Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Apheresis Systems Market $5.5 Billion by 2029

The global market for apheresis systems estimated to reach $5.5 billion by 2029, expanding at a CAGR of 8.9% over the forecast period, driven by up-to-date technologies, and its wide range of clinical applications worldwide.

  • Other factors supporting the growth of global apheresis equipment market include high demand for plasma, increasing number of platelet donors, and whole blood collection related products and automated blood component collection systems in the emerging countries.
    • However, the decline in sales in part attributed to negative impact from a fluctuation in demand triggered by a decrease in the number of blood donations.
Global Apheresis Systems Market

Apheresis (also known as pheresis or therapeutic pheresis) procedure utilizes specialized equipment to remove selected blood constituents (plasma, leukocytes, platelets, or cells) from whole blood. The remainder is then re-transfused into the person from whom the blood was taken.

  • Apheresis systems collect and separate blood components for donation; they can also remove or exchange substances in therapeutic procedures.
    • Apheresis system enables automated red blood cells (RBCs) exchange for patients with sickle cell disease and therapeutic plasma exchange for patients with various other blood diseases.
      • Diseases commonly treated with apheresis include thrombotic thrombocytopenic purpura (TTP), Guillain-Barre syndrome (GBS), myasthenia gravis, autoimmune polyneuropathies, Waldenstrom’s macroglobulinemia, Goodpasture’s syndrome, rapidly progressive glomerulonephritis, cryoglobulinemia, sickle cell disease, and pulmonary renal syndrome.

Therapeutic apheresis is used on patients with Goodpasture syndrome, preeclampsia and eclampsia in pregnancy, leukostasis cause by elevated white blood count in leukemia, systemic lupus, vasculitis, polymyositis or dermatomyositis, severe rheumatoid arthritis, or to reduce the risk of antibody-mediated rejection of organ transplants.

  • Therapeutic apheresis procedures can be classified as either the exchange of blood components or the selective removal of specific cells. A portion of the blood is removed or treated, with the remaining components being returned to the patient.
    • Therapeutic apheresis (TA) is an extracorporeal blood purification method employed in treating those of the renal diseases, pathogenesis and clinical course of which depend on the accumulation of the immune complexes, allo- or autoantibodies, cryo- or immunoglobulins in the patient’s plasma.

According to American Society for Apheresis (ASFA), apheresis technology is expensive as well as technically and medically demanding, and low and median income countries have different experiences to share with the rest of the world.

  • Apheresis procedures also require resources taken for granted in the developed world, such as reliable electrical power, that can be unpredictable in parts of the developing world.
    • On the other hand, it was obvious that there are significant disparities in access to apheresis within the same country (such as in Brazil), as well as between neighboring nations in Africa and South America.
Apheresis Equipment Market

The global apheresis equipment market report provides market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR%, 2023 to 2029). 

The global market apheresis equipment segmented by application (neurological disorders, hematology disorders, renal disorders, other disorders such as Babesiosis, venom overdose, etc.), by procedure type (plasmapheresis, photopheresis, leukapheresis, plateletpheresis, LDL apheresis, erythrocytaperesis, lymphapheresis, lipidpheresis), technology(centrifugation, membrane filtration), and geography.

  • By application, the neurological disorders segment accounted for the largest share of total market for apheresis systems, owing to discovery of etiological factors of degenerative neurological diseases.
    • The neurological application segment also anticipated to grow at the fastest double-digit rate during the forecast period.
  • In terms of procedure types, the plasmapheresis procedures segment dominated the market, accounting for more than 50% of the total market, among the other procedure types for apheresis.
    • The use of plasmapheresis in a wide range of diseases led to its dominant position. Plasmapheresis also may be done therapeutically to remove certain deleterious substances (e.g. autoantibodies, immune complexes) that circulate in plasma.
      • However, the photopheresis procedures segment forecast to be the fastest growing segment in the procedures market, driven largely by increasing prevalence of various diseases such as cancer, and skin disorders as well as increasing efficacy of the plasmapheresis procedure.
    • The LDL apheresis is an invasive procedure by which LDL-cholesterol is removed from the blood (in a process similar to kidney dialysis) and is usually reserved for high-risk patients with very high cholesterol who are unable to achieve their cholesterol-lowering goals on any other therapy.
      • It reduces LDL levels by 50-75% in the short-term but levels quickly rebound, necessitating frequent repeat treatment.
  • Based on the technologies, the membrane filtration technologies segment registered higher market share compared to the centrifugation technology, as it is more beneficial in filtration of blood components in different therapeutic methods of apheresis.

The global apheresis systems market research report is divided by geography North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America region led the total apheresis systems market, driven by increasing demand for apheresis equipment, favorable reimbursement policies and availability of modern healthcare infrastructure.
    • Apheresis can only be performed in specialized centers and the availability of these varies by country, with the highest numbers being found in Germany and the US.
      • The process can cost up to $100,000 for each patient per year in the US or up to €60,000 in Germany, where there are 200 centers.
        • In the US, there are only approximately 60 apheresis centers and many patients must travel significant distances for the procedure.
  • However, the increasing awareness, improving healthcare infrastructure and purchasing power in emerging countries of the Asia Pacific region are predicted to show double-digit market growth over the forecast period.
  • Terumo Corporation, a global leader in blood component and cellular technologies offers a unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing.

The competitors players operating in the global apheresis systems market and included in the report are Asahi Kasei Kuraray Medical Co., Ltd., B. Braun Melsungen AG, Charles River Laboratories International, Inc. (Hemacare Corporation), Fresenius Kabi AG (Fenwal Holdings, Inc.), Haemonetics Corporation, Mallinckrodt Pharmaceuticals (Therakos, Inc.), and Terumo Corporation.

  • Application
    • Neurological Disorders
    • Hematology Disorders
    • Renal Disorders
    • Other Disorders (Babesiosis, Venom Overdose, Others)
  • Procedure Type
    • Plasmapheresis
    • Photopheresis
    • Leukapheresis
    • Plateletpheresis
    • LDL Aphaeresis
    • Erythrocytaperesis
    • Other Procedures (Lymphapheresis, Lipidpheresis, Others)
  • Technology
    • Centrifugation
    • Membrane Filtration
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Asahi Kasei Kuraray Medical Co., Ltd.
    • B. Braun Melsungen AG
    • Charles River Laboratories International, Inc. (Hemacare Corporation)
    • Fresenius Kabi AG (Fenwal Holdings, Inc.)
    • Haemonetics Corporation
    • Mallinckrodt Pharmaceuticals (Therakos, Inc.)
    • Terumo Corporation

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com